Cost-effectiveness analysis of Tocilizumab compared to Adalimumab in the treatment of severe active rheumatoid arthritis in Iran
This study provides convincing evidence of the cost-effectiveness of TCZ compared to ADA in the treatment of active severe RA in Iran.
Authors
- Yalda Metghalchi
- Alireza Kargar (ORCID: https://orcid.org/0000-0001-9582-8879)
- Neda Yaghoubi (ORCID: https://orcid.org/0000-0002-0466-9903)
- Nazila Yousefi (ORCID: https://orcid.org/0000-0001-8079-7424)
- Soheila Rezaei (ORCID: https://orcid.org/0000-0001-9077-6715)
- Razieh Ahmadi
- Marzieh Zargaran
Institutions
- Shahid Beheshti University of Medical Sciences (IR)
- Tehran University of Medical Sciences (IR)
Publication Details
- Journal
- Cost Effectiveness and Resource Allocation
- Published
- 2024-11-13
- DOI
- https://doi.org/10.1186/s12962-024-00592-7
- Primary Topic
- Rheumatoid Arthritis Research and Therapies
- Type
- article
- Field-Weighted Citation Impact
- 0.00